Illumina (NASDAQ:ILMN) had its price target upped by Piper Jaffray Companies to $274.00 in a research report report published on Thursday, January 4th. They currently have an overweight rating on the life sciences company’s stock.

Other analysts have also recently issued research reports about the stock. Zacks Investment Research upgraded shares of Illumina from a hold rating to a buy rating and set a $229.00 price target on the stock in a research note on Friday, October 27th. Vetr upgraded shares of Illumina from a hold rating to a buy rating and set a $217.50 price target on the stock in a research note on Tuesday, September 19th. Argus boosted their price target on shares of Illumina from $205.00 to $235.00 and gave the stock a buy rating in a research note on Wednesday, September 13th. Deutsche Bank upgraded shares of Illumina from a hold rating to a buy rating and decreased their price target for the stock from $195.00 to $160.00 in a research note on Monday, October 23rd. Finally, Canaccord Genuity reiterated a buy rating and issued a $230.00 price target (up previously from $215.00) on shares of Illumina in a research note on Thursday, October 12th. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and fourteen have assigned a buy rating to the company’s stock. The company has a consensus rating of Buy and a consensus price target of $223.88.

Illumina (NASDAQ ILMN) traded down $0.21 on Thursday, hitting $241.57. 191,058 shares of the company were exchanged, compared to its average volume of 928,928. The stock has a market cap of $35,745.18, a PE ratio of 45.53, a price-to-earnings-growth ratio of 3.28 and a beta of 0.79. Illumina has a 52 week low of $156.50 and a 52 week high of $248.97. The company has a debt-to-equity ratio of 0.41, a quick ratio of 3.73 and a current ratio of 4.22.

In related news, SVP Charles Dadswell sold 1,609 shares of the company’s stock in a transaction dated Friday, November 3rd. The shares were sold at an average price of $207.88, for a total transaction of $334,478.92. Following the transaction, the senior vice president now directly owns 7,217 shares in the company, valued at approximately $1,500,269.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Marc Stapley sold 2,000 shares of the company’s stock in a transaction dated Wednesday, November 15th. The shares were sold at an average price of $205.48, for a total transaction of $410,960.00. Following the transaction, the executive vice president now owns 30,370 shares in the company, valued at $6,240,427.60. The disclosure for this sale can be found here. Insiders have sold a total of 132,671 shares of company stock worth $29,003,868 over the last quarter. 0.89% of the stock is currently owned by insiders.

Institutional investors have recently added to or reduced their stakes in the business. Advisory Services Network LLC boosted its position in Illumina by 13.0% in the 2nd quarter. Advisory Services Network LLC now owns 772 shares of the life sciences company’s stock valued at $134,000 after buying an additional 89 shares during the period. Dupont Capital Management Corp purchased a new stake in Illumina in the 3rd quarter valued at about $153,000. Patten Group Inc. boosted its position in Illumina by 71.1% in the 3rd quarter. Patten Group Inc. now owns 1,480 shares of the life sciences company’s stock valued at $172,000 after buying an additional 615 shares during the period. Riverbridge Partners LLC purchased a new stake in Illumina in the 4th quarter valued at about $202,000. Finally, Outfitter Advisors LTD. purchased a new stake in Illumina in the 4th quarter valued at about $205,000. 91.71% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY WARNING: This report was published by Marea Informative and is the sole property of of Marea Informative. If you are viewing this report on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The original version of this report can be read at https://www.mareainformativa.com/illumina-ilmn-price-target-raised-to-274-00-updated-updated-updated/126636/.

About Illumina

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Analyst Recommendations for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.